Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -27K | -28K | -25K | -40K | -69K |
| Operating Income | -9M | -8M | -9M | -11M | -12M |
| EBITDA | -9M | -8M | -9M | -11M | -12M |
| Net Income | -9M | -15M | -120K | -11M | -12M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.98
-8.41% today
1Y Change
-88.48%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Revelation Biosciences, Inc. (REVB) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.98 and down 88.5% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +72.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +72.7%, free cash flow +54.9% with operating margin 0.0% and ROIC -94.4%. Stock Foundry combines REVB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REVB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
REVB Max Drawdown
-92.23%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for REVB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$12.0M
-10.7% YoY
Free Cash Flow
-$11.2M
-0.0% YoY
Revenue Growth
+0.0%
EPS Growth
+72.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -27K | -28K | -25K | -40K | -69K |
| Operating Income | -9M | -8M | -9M | -11M | -12M |
| EBITDA | -9M | -8M | -9M | -11M | -12M |
| Net Income | -9M | -15M | -120K | -11M | -12M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11M | 6M | 12M | 5M | 1M |
| Total Assets | 12M | 7M | 12M | 6M | 2M |
| Total Liabilities | 3M | 2M | 6M | 4M | 2M |
| Shareholder Equity | 9M | 5M | 7M | 1M | -99K |
| Total Debt | 747K | 0 | 0 | 0 | 17K |
| Net Debt | -10M | -6M | -12M | -5M | -1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
11M
+1.1% YoY
Capital Expenditures
132K
Free Cash Flow
11M
-0.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-134.2%
Debt / Equity
0.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.